-
Mashup Score: 0HER2+ Breast Cancer With Immune-Related Gene Signatures May Be Eligible for De-Escalation Approaches - 3 year(s) ago
Distinct gene signatures, with the exception of estrogen receptor signaling and BRCAness, are associated with pathologic complete response and invasive disease-free survival, in patients with HER2-positive breast cancer who received trastuzumab and pertuzumab alone or in combination with paclitaxel.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3
The differentiated TROP2-directed antibody-drug conjugate datopotamab deruxtecan was found to have promising antitumor activity with a manageable safety profile in heavily pretreated patients with triple-negative breast cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Datopotamab Deruxtecan Shows Encouraging Preliminary Safety, Efficacy in TNBC @ABhealer108 @MGHCancerCenter @myESMO #ESMOBreast21 #bcsm https://t.co/gakJomZOYt
-
-
Mashup Score: 12
Translational findings from the WSG-ADAPT study
Source: www.esmo.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ESMOBreast21: Identification of Potential #Biomarkers for Clinical Benefit Following Dual Neoadjuvant #Anti-HER2 Blockade in HER2-positive/HR-negative #earlyBreastCancer: Translational findings from the WSG-ADAPT study https://t.co/A1rJsfZDId #HER2 #bcsm #BreastCancer https://t.co/pO3tDKbC6X
-
-
Mashup Score: 3The Switch of Breast Tumours to HER2-Low Status in Recurrence Might Provide Greater Therapeutic Options [ESMO Press Release] - 3 year(s) ago
The finding that breast tumours can evolve to express low HER2 potentially widens the number of patients who can benefit from new investigational…
Source: www.esmo.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ESMOBreast21: @bozovicspa highlights interesting results from studies looking to into #HER2-low #breastcancer and consequences for future developements. More news from today on #HER2 low breast cancer https://t.co/xi6zJ9V92n #bcsm https://t.co/HmUq5G35cP
-
-
Mashup Score: 0Risk of Distant Recurrence of ER-Positive Breast Cancer in Premenopausal Women According to 70-Gene Risk Signature - 3 year(s) ago
Swedish investigators found that clinical benefit with endocrine therapy differs by risk group
Source: www.esmo.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ESMOBreast21: Risk of Distant Recurrence of ER-Positive #BreastCancer in #Premenopausal Women According to 70-Gene Risk Signature. Swedish investigators found that clinical benefit with #endocrinetherapy differs by risk group. https://t.co/SdCuteLFlV #bcsm @karolinskainst https://t.co/ZekK9JXRop
-
-
Mashup Score: 2
In the KATHERINE study (NCT01772472), patients with residual invasive early breast cancer (EBC) after neoadjuvant chemotherapy (NACT) plus HER2-targeted therapy had a 50% reduction in risk of recurrence or death with adjuvant T-DM1 versus trastuzumab. Here, we present additional exploratory safety and efficacy analyses.
Source: Annals of OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
While following the last day of #ESMOBreast21 , check out the results of the subgroup analyses from KATHERINE, the phase III RCT that led to the regulatory approval of adjuvant T-DM1 in the setting of residual disease 👉 https://t.co/ZO8o9ZbmF0 #bcsm #openaccess https://t.co/d1pavcAXmi
-
-
Mashup Score: 0
Thomas Bachelot, MD, discussed how to approach treatment of patients with HER2-positive breast cancer and CNS metastases and the impact of tucatinib in this population.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Bachelot Spotlights Promise of Tucatinib for CNS Metastases in HER2+ Breast Cancer @CLCCLeonBerard @myESMO #ESMOBreast21 https://t.co/EAX7qcj3iN
-
-
Mashup Score: 0Retesting for HER2 Upon Breast Cancer Relapse May Provide New Therapeutic Opportunities - 3 year(s) ago
Approximately 30% of breast cancer tumors can covert from, or to, HER2-low status, underscoring the need to retest for HER2 expression upon relapse.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Retesting for HER2 Upon Breast Cancer Relapse May Provide New Therapeutic Opportunities @UniPadova @myESMO #ESMOBreast21 #bcsm https://t.co/D6hk6zFDdx
-
-
Mashup Score: 2The Switch of Breast Tumours to HER2-Low Status in Recurrence Might Provide Greater Therapeutic Options [ESMO Press Release] - 3 year(s) ago
The finding that breast tumours can evolve to express low HER2 potentially widens the number of patients who can benefit from new investigational…
Source: www.esmo.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ESMOBreast21: Breast tumours can evolve to express low #HER2, potentially widening no of pts who can benefit from new investigational agents, such as novel antibody-drug conjugates, currently in CTs. 👉https://t.co/xi6zJ9V92n @FedeMiglietta @prat_aleix #bcsm #breastcancer https://t.co/ow9xwlSrSy
-
-
Mashup Score: 6Conference Calendar - ESMO Breast Cancer Virtual Congress 2021 - 3 year(s) ago
YOC Forum – The future of academic research in oncology: Is there a role for young oncologists? Young oncologist session Live introduction (ID 313) Lecture Time 12:45 – 12:50 YOC Forum – The future of academic research in…
Source: cslide.ctimeetingtech.comCategories: Hem/Oncs, Latest HeadlinesTweet-
The last day of #ESMOBreast21 is about to start with a great #YOC session addressing the future of academic #research in #oncology and the role of young oncologists: of course with a great faculty @FAndreMD @DebFumagalli @kevinpunie ! @OncoAlert @myESMO https://t.co/4EG7mwf6Np https://t.co/uFc21mMikO
-
HER2+ Breast Cancer With Immune-Related Gene Signatures May Be Eligible for De-Escalation Approaches @myESMO #ESMOBreast21 #bcsm https://t.co/VRMyVa9rYq